Dimenhydrinate
Aminoalkyl Ethers
Sold as Motion Sickness · DRAMAMINE · Dramamine for Kids · ANTI-NAUSEANT · Motion Sickness Relief
- Drug class
- Aminoalkyl Ethers
- Availability
- Over-the-counter
- Routes
- Intravenous, Intramuscular, Rectal, Oral
- Markets covered
- 3
- Products on record
- 32
- FDA reports (12 mo)
- 639
Overview
Plain-language summary, compiled from the cited regulatory records
Dimenhydrinate is an active ingredient classified as an Aminoalkyl Ether [1]. It is approved for the prevention and treatment of symptoms associated with motion sickness, including nausea, vomiting, and dizziness [1].
This ingredient is available under various brand names, such as Motion Sickness Relief, Motion Sickness, and Dramamine for Kids [1]. In the past 12 months, there have been 639 adverse event reports associated with dimenhydrinate [2]. The most frequently reported adverse events include nausea, fatigue, off-label use, vomiting, and malaise [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 26 | December 5, 2025 |
| US United States | FDA | 3 | May 7, 2026 |
| GB United Kingdom | MHRA | 3 | October 3, 2025 |
CACanada· Health Canada
26 products
Uses
AND CLINICAL USE ................................................................................................... 4 CONTRAINDICATIONS .........................................................................................................................
4 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS .........................................................................................................................
7 DRUG INTERACTIONS ......................................................................................................................... 8 DOSAGE AND ADMINISTRATION .....................................................................................................
8 ACTION AND CLINICAL PHARMACOLOGY .................................................................................. 10 DOSAGE FORMS, COMPOSITION AND PACKAGING ................................................................... 11 STORAGE AND STABILITY ...............................................................................................................
USUnited States· FDA
3 products
Uses
Uses for prevention and treatment of these symptoms associated with motion sickness: nausea vomiting dizziness
How to take
GBUnited Kingdom· MHRA
3 products
Uses
Treatment of vertigo symptoms of various origins. Arlevert is indicated in adults.
How to take
Drug interactions
Known interactions involving Dimenhydrinate. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 258. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 00013609 · revised March 22, 2025
- [2]FDA DailyMed · 00a327c6-6b86-47… · revised May 7, 2026 [PDF]
- [3]MHRA (UK) · PL112490001 · revised June 20, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.